Test: Who Should Have It?
Thrombophilia testing is not routine screening for everyone; defining the indication correctly reduces both cost and the risk of misinterpretation. The following groups benefit most:
Clear Indications
- Thrombosis under 45: DVT or pulmonary embolism without an obvious trigger (surgery, prolonged bed rest).
- Recurrent pregnancy loss: Especially after the 10th week; the panel is considered at two or more events.
- Unusual thrombosis sites: Mesenteric, hepatic, portal or cerebral vein thrombosis.
- Family history: Multiple family members with early thrombosis or known carriage.
- Neonatal purpura fulminans history: Family screening for Protein C/S deficiency.
Conditional Indications
- Women planning estrogen therapy (contraceptive pills, HRT) with a risky family history.
- Patients with repeated organ pathologies (e.g. hepatic veins).
- First-degree relatives of young unexplained-thrombosis patients (with counseling).
Who Should Not Be Tested?
- First thrombosis in old age with a clear trigger (major surgery, cancer) — management usually unchanged.
- Non-recurring superficial vein thrombosis.
- Screening "out of curiosity" without indication; the result can create false anxiety.
Test Timing
Genetic tests (FVL, Prothrombin, MTHFR) are always reliable. For Protein C, S and antithrombin levels: blood should be drawn at least 4-6 weeks after acute thrombosis and ideally during an anticoagulant-free interval. Warfarin distorts these assays; planning is done with your physician.
Family Screening
When carriage is identified, first-degree relatives should be informed. Screening affects pregnancy planning, hormonal therapy decisions and surgical prophylaxis.
Conclusion
The indication should be defined with a physician, the test taken at the right time and the result interpreted in clinical context. Our laboratory offers personalized reports and interpretation support in cooperation with your clinical team.